Nymox Recommended in Three Recent Independent Analyst Reports.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Nymox Now Rated "Strong Speculative Buy" by Dutton Associates, "Buy" by Cohen cohen or kohen (Hebrew: “priest”) Jewish priest descended from Zadok (a descendant of Aaron), priest at the First Temple of Jerusalem. The biblical priesthood was hereditary and male. Independent Research Group, and "Speculative Buy" by WallStreet Research Three current independent analyst reports recommend Nymox Pharmaceutical Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : NYMX NYMX New York Mercantile Exchange ). The most recent recommendation from WallStreet Research was written by Alan Stone on December 22, 2005. The "buy" recommendation from Cohen Independent Research Group was written on December 6, 2005. The "strong speculative buy" recommendation from Dutton Associates was written by Dr. William Prather on November 17, 2005. The Dutton report states, "Based on the assumptions that Nymox will announce a marketing collaborator over the near term and will be in Phase III clinical trials next year at this time, and comparing the current value of Nymox to an average of comparable biopharmaceutical companies in Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA trials, we arrive at our 12-month price target on the common shares of $6.25 and our rating of Strong Speculative Buy." The WallStreet Research report states, "With no long-term debt Long-Term Debt Loans and financial obligations lasting over one year. Notes: For example debts obligations such as bonds and notes which have maturities greater than one year would be considered long-term debt. and a low burn rate compared to industry standards, especially considering the number of marketed products and significant projects in the pipeline, the Company appears to be an excellent buying opportunity." According to the Cohen Independent Research Group, "We continue to rate Nymox Pharmaceutical Corp a BUY, with a base price of $7.20. Primary catalysts in the near future are: 1) increased orders for NicAlert/TobacAlert tests; 2) completion of the Phase II for NX-1207, the BPH BPH abbr. benign prostatic hyperplasia BPH Benign prostatic hypertrophy, a very common noncancerous cause of prostatic enlargement in older men. treatment; 3) tie-up with a large pharmaceuticals company for NX-1207, if Phase II results are positive; and 4) any agreement related to the marketing of NX-4720. Long-term catalysts include: 1) the initiation of Phase III trial for NX-1207; and 2) the approval and timing for launch of AlzheimAlert test kits in the U.S." More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669. The above analyst reports contain disclaimers stated in each individual report, and also stated in Nymox's initial press releases on the issuance of the reports, which concern risks, uncertainties, and limitations of the reports. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion